A comprehensive functional analysis of TP53 mutations in human leukemia may refute a working hypothesis - primarily based on mouse studies - that missense mutations confer new cancer-causing functions to the p53 tumor suppressor protein; the new study instead suggests that these mutations exert a "dominant-negative" effect that reduces the cancer-suppressing activity of wild-type p53, the authors say.
The TP53 gene was discovered 40 years ago and it now known to be the most frequently mutated gene in human cancer. Initially, TP53 was mischaracterized as an oncogene but human genetic studies ultimately established that it encodes a tumor suppressor. But how cancer-associated mutations in TP53 alter the function of wild-type p53 has continued to be the subject of debate.
The vast majority of TP53 mutations across all cancer types are missense mutations, which can result in non-functional or dysfunctional p53. Based largely on mouse model experiments, it has been hypothesized that certain missense mutations can transform the p53 tumor suppressor into a tumor promoter via so-called oncogenic "gain of function" (GOF) effects.
To explore the functional consequences of p53 mutations, researchers performed a comprehensive analysis of TP53 mutations in human myeloid leukemia. Using CRISPR/Cas9 gene editing technology, the authors generated isogenic human leukemia cell lines featuring the most common p53 missense variants.
This isogenic analysis - as well as comprehensive mutational screening, in vivo experiments in mice and an analysis of clinical data - did not support the notion that missense mutations confer new oncogenic functions to the p53 tumor suppressor protein.
Instead, the authors discovered that the mutations confer either loss of function effects or dominant-negative effects (DNE) that reduce the tumor-supressing efficacy of wild-type p53 in human leukemia. In mice, the DNE of p53 missense variants confers a selective advantage to hematopoietic cells on DNA damage. Analysis of clinical outcomes in patients with acute myeloid leukemia showed no evidence of GOF for TP53missense mutations. Thus, a DNE is the primary unit of selection for TP53 missense mutations in myeloid malignancies.
https://science.sciencemag.org/content/365/6453/599
Type of TP53 mutations and their affect in cancer
- 2,612 views
- Added
Edited
Latest News
Which of the two DNA strand…
By newseditor
Posted 16 Jun
Microglia depletion prevent…
By newseditor
Posted 16 Jun
Colorectal cancer stem cell…
By newseditor
Posted 16 Jun
Paranoia in the brain
By newseditor
Posted 16 Jun
In-vitro 3D culture of func…
By newseditor
Posted 15 Jun
Other Top Stories
Protein required for metastatic potential in breast cancer identified
Read more
Bovine leukemia virus (BLV) in cattle linked to human breast cancer
Read more
Programmed cell death receptors on tumor cells promote cancer growth
Read more
Factors involved in muscle wasting (cachexia) in cancer identified!
Read more
Researchers disguise drugs as platelets to target cancer
Read more
Protocols
Bioengineered human colon o…
By newseditor
Posted 14 Jun
Development of an efficient…
By newseditor
Posted 12 Jun
A co-culture system of macr…
By newseditor
Posted 10 Jun
Analysis of 3D pathology sa…
By newseditor
Posted 08 Jun
Long-term expandable mouse…
By newseditor
Posted 07 Jun
Publications
Lost in translation: challe…
By newseditor
Posted 17 Jun
Pathways for macrophage upt…
By newseditor
Posted 16 Jun
Common and distinct neural…
By newseditor
Posted 16 Jun
Strand-resolved mutagenicit…
By newseditor
Posted 16 Jun
Innate-like T cells in live…
By newseditor
Posted 16 Jun
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar